
GHRP-2 (pralmorelin, KP-102) is one of the most clinically studied growth hormone releasing peptides. Originally developed as a diagnostic tool for GH deficiency, it has become a reference compound for understanding how synthetic ghrelin mimetics drive pulsatile GH release. GHRP-2 is not FDA-approved for therapeutic use. This is not medical advice.
Note: GHRP-2 is NOT in the cheat sheet. The protocol below is a Community Protocol based on clinical research data and community experience.
| Parameter |
Community Protocol |
| Dose |
100-300 mcg per injection |
| Route |
Subcutaneous injection (abdomen or thigh) |
| Timing |
Empty stomach (30-60 min before meals) |
| Frequency |
2-3 times daily, 3+ hours apart; 5 days on / 2 days off |
| Cycle |
8 weeks on, 8 weeks off |
| Vial size |
10 mg |
| Reconstitution |
5 mL bacteriostatic water → 2 mg/mL |
| Draw amount |
5 units (100 mcg) / 10 units (200 mcg) / 15 units (300 mcg) |
| Storage |
Refrigerate, use within 28 days |
Most common approach: 100-200 mcg per injection (the clinical research range), 2-3 times daily on empty stomach. Common timing: morning fasted, pre-workout, and before bed.
For the full GHRP-2 peptide profile, vendor pricing, and stack protocols, see our GHRP-2 peptide page.
Cycling Details
GHRP-2 doesn't use loading phases. Run consistent 100-300 mcg doses, 2-3 times daily, 5 days on / 2 days off. A five-day treatment study showed response attenuation with consecutive daily use (Raun et al., 1998), making the 5-on/2-off pattern important.
8 weeks on, 8 weeks off for long-term cycling. The short half-life (~15-30 minutes) means each injection provides an acute GH pulse rather than sustained elevation.
Empty stomach essential: Inject 30-60 minutes before eating or 2+ hours after meals. Elevated blood glucose and free fatty acids significantly blunt the GH response.
Common timing: Morning fasted + before bed (2x/day), or morning fasted + pre-workout + before bed (3x/day).
Routes of Administration
Subcutaneous injection (standard): Belly fat, thigh, or anywhere with SC tissue. Volume: 0.1-0.2 mL with insulin syringe (29-31 gauge). Rotate sites.
Reconstitution Quick Reference
| Vial Size |
BAC Water |
Concentration |
100 mcg |
200 mcg |
300 mcg |
| 10 mg |
5 mL |
2 mg/mL |
5 units |
10 units |
15 units |
Math: 10,000 mcg / 5 mL = 2,000 mcg/mL. For 200 mcg: 200 / 2,000 = 0.1 mL = 10 units. One vial lasts 50 doses at 200 mcg.
Swirl gently -- do not shake. Refrigerate at 2-8°C and use within 28 days. For step-by-step instructions, see the Reconstitution Calculator.
Where These Numbers Come From
Unlike many research peptides, GHRP-2 community doses closely align with published clinical research.
Diagnostic testing: 100 mcg (1 mcg/kg) is the standard dose for GH deficiency diagnosis, producing robust GH pulses in healthy individuals (PMID: 17609397).
Research studies: 200 mcg (2-3 mcg/kg) used in studies examining GH secretory dynamics (PMID: 18703567).
Plateau effect: Higher doses (300+ mcg) don't increase GH proportionally but do increase cortisol and prolactin side effects.
GH response data: Peak GH levels of 30-80 ng/mL at 100-200 mcg doses. Time to peak: 30-60 minutes. Duration: 2-3 hours elevated. Synergy with GHRH: 3-10x greater response when combined.
Why doses align with research: GHRP-2 is approved in Japan as pralmorelin for GH testing. This established effective dose ranges directly, unlike most peptides that require extrapolation from animal studies.
Stacking Protocols
| Stack |
Components |
Purpose |
| Most Evidence-Supported |
GHRP-2 100-200 mcg + CJC-1295 200 mcg (simultaneous, PM) |
GHSR-1a + GHRHR synergy = 3-10x GH release |
| + Sermorelin |
GHRP-2 100-200 mcg + Sermorelin |
Shorter-acting GHRH alternative |
GHRP-2 + GHRH synergy leverages two different receptor pathways: GHRP-2 via GHSR-1a (calcium/PKC) and CJC-1295 via GHRHR (cAMP/PKA) (Veldhuis et al., 2009).
For comprehensive stacking strategies, see our Peptide Stacking Guide.
Side Effects & Safety

- Cortisol elevation -- transient ACTH/cortisol increase via HPA axis; dose-dependent, mild at 100-200 mcg
- Prolactin elevation -- less than hexarelin, more than ipamorelin; returns to baseline within 2-3 hours
- Appetite stimulation -- ghrelin mimetic effect, peaks 20-30 min post-injection; milder than GHRP-6
- Water retention -- mild, GH-mediated sodium retention
- Desensitization -- consecutive daily use leads to response attenuation (hence 5 on / 2 off)
- Injection site reactions -- standard for SC peptides
GHRP family comparison:
| GHRP |
GH Release |
Cortisol/Prolactin |
Appetite |
| Ipamorelin |
Moderate |
Minimal |
Minimal |
| GHRP-2 |
Strong |
Moderate |
Mild |
| GHRP-6 |
Strong |
Moderate |
Strong |
| Hexarelin |
Strongest |
Highest |
Moderate |
Frequently Asked Questions
What is the standard GHRP-2 dose?
100-300 mcg per injection, 2-3 times daily on empty stomach, 5 on / 2 off, 8 weeks on / 8 weeks off. This matches clinical doses of 1-2 mcg/kg.
Should I take GHRP-2 on an empty stomach?
Yes -- 30-60 minutes before eating or 2+ hours after meals. Blood glucose and free fatty acids blunt GH response.
Does GHRP-2 cause hunger like GHRP-6?
Milder. GHRP-2 causes mild appetite stimulation that peaks 20-30 minutes post-injection. GHRP-6 causes significantly more hunger.
Can GHRP-2 be stacked with CJC-1295?
Yes -- the most evidence-supported GHRP + GHRH stack. Synergistic GH release 3-10x greater than either alone.
Does GHRP-2 increase cortisol?
Yes -- dose-dependent ACTH and cortisol elevation via hypothalamic CRF pathways. Typically mild at standard doses.
What's the difference between GHRP-2 and ipamorelin?
GHRP-2 produces stronger GH release but with more cortisol/prolactin elevation. Ipamorelin is more selective with minimal side effects but less potent. See our GHRP comparison guide.
Does GHRP-2 suppress natural GH production?
No -- it stimulates endogenous production through the pituitary. However, chronic use may desensitize GHSR-1a receptors, making cycling important.
References
| Citation |
Topic |
PMID |
| Bowers CY, Cell Mol Life Sci (1998) |
GHRP overview |
9893708 |
| Howard et al., Science (1996) |
GHSR-1a receptor discovery |
8688086 |
| Kojima et al., Nature (1999) |
Ghrelin identification |
10604470 |
| Simple diagnostic test using GHRP-2, Endocr J (2007) |
Clinical diagnostic applications |
17609397 |
| Secretagogues govern GH waveform, Am J Physiol (2008) |
GH response dynamics |
18703567 |
| Raun et al., Growth Horm IGF Res (1998) |
Desensitization with consecutive use |
9820615 |
| Veldhuis et al., J Clin Endocrinol Metab (2009) |
GHRP + GHRH synergy |
19240251 |
For educational and research purposes only. This is not medical advice. GHRP-2 is a research compound not approved for therapeutic use.